{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:58:03Z","timestamp":1772639883991,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Foundation of CSCO-Shiyao","award":["Y-SY201901-0068"],"award-info":[{"award-number":["Y-SY201901-0068"]}]},{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019540","name":"Science Fund for Distinguished Young Scholars of Zhejiang Province","doi-asserted-by":"publisher","award":["Y22H227294"],"award-info":[{"award-number":["Y22H227294"]}],"id":[{"id":"10.13039\/501100019540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03597-z","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T17:01:45Z","timestamp":1721840505000},"page":"534-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Keda","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0570","authenticated-orcid":false,"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"3597_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","volume":"99","author":"M Scorsetti","year":"2016","unstructured":"Scorsetti M, Leo F, Trama A, D\u2019Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332\u201350.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3597_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/his.15097","volume":"84","author":"J von der Th\u00fcsen","year":"2024","unstructured":"von der Th\u00fcsen J. Thymic epithelial tumours: histopathological classification and differential diagnosis. Histopathology. 2024;84:196\u2013215.","journal-title":"Histopathology"},{"key":"3597_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jtho.2022.11.029","volume":"18","author":"AF Artal-Cortes","year":"2023","unstructured":"Artal-Cortes AF, Verd\u00fan-Aguilar J, M\u00e1rquez-Medina D. Opening windows for thymic tumors. J Thorac Oncol. 2023;18:136\u20138.","journal-title":"J Thorac Oncol"},{"key":"3597_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jtcvs.2019.10.059","volume":"159","author":"CC Frye","year":"2020","unstructured":"Frye CC, Harrison MS, Puri V. Commentary: pleural metastases in thymic tumors: is surgery the answer? J Thorac Cardiovasc Surg. 2020;159:717\u20138.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3597_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","volume":"126","author":"T Berghmans","year":"2018","unstructured":"Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP, et al. Systemic treatments for thymoma and thymic carcinoma: a systematic review. Lung Cancer (Amsterdam, Netherlands). 2018;126:25\u201331.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"3597_CR6","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"3597_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"3597_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"3597_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500\u20138.","journal-title":"J Thorac Oncol"},{"key":"3597_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","volume":"101","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S, Miyoshi H, Nishi T, Hashiguchi T, Mitsuoka M, Takamori S, et al. Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma. Ann Thorac Surg. 2016;101:1361\u20139.","journal-title":"Ann Thorac Surg"},{"key":"3597_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","volume":"174","author":"W Wang","year":"2022","unstructured":"Wang W, Lin G, Hao Y, Guan Y, Zhang Y, Xu C, et al. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study. Eur J Cancer (Oxford, England: 1990). 2022;174:21\u201330.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"3597_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.lungcan.2023.01.003","volume":"176","author":"A Arunachalam","year":"2023","unstructured":"Arunachalam A, Zhang I, Zhao B, Frederickson AM, Catherine PM. Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: a systematic literature review and meta-analysis. Lung Cancer (Amsterdam, Netherlands). 2023;176:132\u20139.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"3597_CR13","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162\u201370.","journal-title":"J Clin Oncol"},{"key":"3597_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/1759-7714.14309","volume":"13","author":"Y Takahara","year":"2022","unstructured":"Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T, et al. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. Thorac Cancer. 2022;13:624\u201330.","journal-title":"Thorac Cancer"},{"key":"3597_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","volume":"140","author":"M Giaj Levra","year":"2020","unstructured":"Giaj Levra M, Cott\u00e9 FE, Corre R, Calvet C, Gaudin AF, Penrod JR, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer (Amsterdam, Netherlands). 2020;140:99\u2013106.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"3597_CR16","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00432-021-03901-2","volume":"148","author":"Z Xu","year":"2022","unstructured":"Xu Z, Hao X, Yang K, Wang Q, Wang J, Lin L, et al. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. J Cancer Res Clin Oncol. 2022;148:3081\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3597_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290:6\u201323.","journal-title":"Immunol Rev"},{"key":"3597_CR18","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","volume":"5","author":"EA Engels","year":"2010","unstructured":"Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5:S260\u20135.","journal-title":"J Thorac Oncol"},{"key":"3597_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347\u201355.","journal-title":"Lancet Oncol"},{"key":"3597_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","volume":"113","author":"Y Katsuya","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer (Oxford, England: 1990). 2019;113:78\u201386.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"3597_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","volume":"7","author":"A Rajan","year":"2019","unstructured":"Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O\u2019Sullivan Coyne G, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269.","journal-title":"J Immunother Cancer"},{"key":"3597_CR22","doi-asserted-by":"publisher","first-page":"11351","DOI":"10.2147\/CMAR.S274830","volume":"12","author":"W Jin","year":"2020","unstructured":"Jin W, Duan JC, Wang ZJ, Lin L, Bai H, Wang J, et al. The effect and safety of anti-PD-1 single\/combination therapy in refractory thymic carcinoma: a case-series study. Cancer Manag Res. 2020;12:11351\u20138.","journal-title":"Cancer Manag Res"},{"issue":"20","key":"3597_CR23","doi-asserted-by":"publisher","first-page":"17987","DOI":"10.1007\/s00432-023-05490-8","volume":"149","author":"M Xu","year":"2023","unstructured":"Xu M, Hao Y, Shi Z, Song Z. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149(20):17987\u201395.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03597-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:22:56Z","timestamp":1738254176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03597-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3597"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03597-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2022\u201363). All patients Individual consent for this retrospective analysis was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}